Sei Investments Co. Cuts Stock Holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO)

Sei Investments Co. decreased its holdings in Organogenesis Holdings Inc. (NASDAQ:ORGO) by 23.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 189,414 shares of the company’s stock after selling 57,998 shares during the quarter. Sei Investments Co. owned 0.15% of Organogenesis worth $606,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its position in Organogenesis by 54.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after buying an additional 1,035,120 shares during the period. State Street Corp grew its holdings in shares of Organogenesis by 0.6% in the third quarter. State Street Corp now owns 1,459,767 shares of the company’s stock valued at $4,175,000 after purchasing an additional 9,090 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Organogenesis by 2.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 948,451 shares of the company’s stock valued at $2,713,000 after buying an additional 23,675 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Organogenesis by 35.5% during the fourth quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company’s stock valued at $1,340,000 after buying an additional 109,762 shares during the period. Finally, Wellington Management Group LLP increased its stake in Organogenesis by 8.0% in the 3rd quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock worth $691,000 after buying an additional 17,842 shares during the period. Hedge funds and other institutional investors own 49.57% of the company’s stock.

Insider Buying and Selling

In other news, Director Michael Joseph Driscoll sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $5.10, for a total value of $127,500.00. Following the transaction, the director now directly owns 166,879 shares in the company, valued at approximately $851,082.90. This trade represents a 13.03 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 36.90% of the stock is owned by company insiders.

Analysts Set New Price Targets

Separately, Morgan Stanley lifted their price objective on shares of Organogenesis from $4.00 to $6.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th.

Organogenesis Stock Up 10.3 %

ORGO opened at $4.08 on Thursday. The stock has a market capitalization of $517.46 million, a P/E ratio of -68.00 and a beta of 1.79. The business’s 50-day simple moving average is $4.30 and its 200-day simple moving average is $3.66. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.74 and a current ratio of 3.09. Organogenesis Holdings Inc. has a one year low of $2.17 and a one year high of $6.71.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.